表面膜V-Y推进片用于耳植入器中延迟并发症的延迟并发症
Beomcho Jun1, Da Yoon Kwon2, Sung-No Jung2
1Department of Otolaryngology-Head and Neck Surgery, The Catholic University of Korea.
The Journal of craniofacial surgery
|May 17, 2024
概括
耳植入物 (CI) 暴露,是一种罕见的并发症,可以在手术后数年发生. 这一案例证明了由于磁器件强度增加而延迟死后,使用V-Y片成功重建.
科学领域:
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
- 神经外科 神经外科
- 整形外科 整形外科 整形外科
背景情况:
- 耳植入器 (CI) 是严重听力损失的标准治疗方法.
- 植入物暴露是一种需要手术干预的重大并发症.
- 延迟的并发症,如膜亡,可以在植入后几年出现.
研究的目的:
- 报告一个在耳植入后延迟膜亡的独特病例.
- 要突出外部装置磁力在延迟并发症中的作用.
- 为这种罕见的并发症提出一个成功的手术管理策略.
主要方法:
- 一个病例研究,一个患者经历了耳植入后8年延迟膜亡.
- 调查潜在的原因,包括来自外部设备的磁力增加.
- 使用表面带V-Y进步进行手术重建.
主要成果:
- 拖延膜亡发生在耳植入后8年.
- 这种并发症归因于外部设备的磁力增加.
- 通过V-Y进步实现了成功的重建.
结论:
- 耳植入后延迟膜亡是一种罕见但可能的并发症.
- 外部设备管理至关重要,即使在植入后数年.
- 表面膜V-Y推进片提供了一个可行的重建选项.
相关概念视频
Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...


